ObsEva (NASDAQ:OBSV) Earns Hold Rating from Analysts at StockNews.com

Posted by on Dec 4th, 2024

StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV – Free Report) in a research report released on Sunday. The firm issued a hold rating on the stock.

ObsEva Price Performance

The company has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68. The business has a fifty day simple moving average of $0.01. ObsEva has a 12-month low of $0.08 and a 12-month high of $2.14.

About ObsEva

(Get Free Report)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Featured Stories

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.